The Ash conference is usually a mecca for cell therapy followers. Its 2020 instalment features plenty of Car-T and Car-NK presentations, though investors might rue the fact that these risk being overshadowed by antibody modalities.

Clinical data to watch on adoptive cell therapies include those on Fates allogeneic Car-NK project FT596 and Celyads Cyad-02, a Car using short hairpin RNA technology. Meanwhile, Allovir will want to justify enthusiasm for its recent flotation, whileBCMA-targeted multiple myeloma assets fight to stand out from the crowd.

The most advanced anti-BCMA Car-T therapy is Bristol Myers Squibb/Bluebirds ide-cel, which faces a March 27, 2021 US FDA action date despite an earlier refuse-to-file letter. The asset to watch, however, is Johnson & Johnson/Legend Biotechs cilta-cel, whose Cartitude-1 study is showing a remarkable 95% remission rate, according to the Ash abstract.

Not only that, but Bristol/Bluebirds follow-up, bb21217, looks disappointing, Ash data suggest. A US NCI group including Dr James Kochenderfer, who has also worked on ide-cel, is separately presenting clinical results on a new approach, FHVH-BCMA-T, which uses a heavy chain antibody fragment rather than the normal scFv.

With most abstracts citing relatively early data cut-offs, updates at Ash itself will be keenly awaited. Among these Poseida will no doubt field questions if responses to P-BCMA-101 continue to lookbetter at low than at high doses.

Long time coming

First clinical data on FT596, Fates first Car-modified NK cell approach, have been a long time coming: the FDA signed off the IND in September 2019, but the trial did not start until April this year.

Even so there might be disappointment as the Ash abstract details only a single case study, in a lymphoma subject who went into partial response after a single dose. Expectations for FT596 are high given the 73% response rate cited for an unrelated anti-CD19 Car-NK project run by MD Andersons Dr Katy Rezvani.

There might be more on FT596 at Ash, but some analysts are reining in expectations of meaningful data before next year. In the unmodified NK cell sphere, meanwhile, FC21-NK data could support Sanofis decision to buy Kiadis for $358m this month.

Celyad has been working on Car-T cells targeting NKG2D ligands for some time, but Ash will feature the first clinical data on Cyad-02, a construct that aims to improve on an earlier iteration, Cyad-01.

One problem with Cyad-01 is Car-T fratricide, caused by T cells' own transient expression ofNKG2D ligands; Cyad-02 aims to silence these ligands using shRNA technology. The Ash abstract says Cyad-02 showed threefold better expansion than Cyad-01, and promises to deliver preliminary clinical activity data.

While Cyad-02 is an autologous therapy, Celyad is separately developing allogeneic Cars. One of its allogeneic approaches also usesshRNA for gene silencing, so the Cyad-02 data could provide proof of concept beyond the use in the abstract.

Allogeneic therapies will of course be aired extensively at Ash, and a presidential symposium on 8 December will see UCLAs Dr Gay Crooks discussing universal cell sources. Dr Crookss pluripotent stem cell generation technology was licensed to Kite before that company was bought by Gilead.

Other presentations of general interest include a paper suggesting that CD5 knock-out enhances Car-T cell activity, and another claiming that aberrations in CD58 curtail the efficacy of Yescarta. The latter is also being highlighted at a December 5 press briefing, along with preclinical data on Allovirs anti-Covid-19 T-cell therapy ALVR109.

Investors in Allovir, whose stock has doubled since the group raised $318m in a July IPO, will pay close attention.

Ash 2020 will take place in virtual format on December 5-8.

Vantage analysis previously summarised upcoming Ash presentations that resulted in early share price moves, cancer-focused abstracts outside cell therapy, and those in non-oncology indications.

View original post here:

Ash 2020 cell therapy preview the battle for recognition - Vantage

Animal Stem Cell Therapy Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Animal Stem Cell Therapy Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Animal Stem Cell Therapy industry. Both established and new players in Animal Stem Cell Therapy industries can use the report to understand the Animal Stem Cell Therapy market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14828170

Analysis of the Market:

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

The classification of animal stem cell therapy includes dogs, horses and others. And the proportion of dogs in 2017 is about 50.42%, and the proportion is in increasing trend from 2013 to 2017.

The global Animal Stem Cell Therapy market is valued at 31 million USD in 2020 is expected to reach 291.6 million USD by the end of 2026, growing at a CAGR of 37.3% during 2021-2026.

This report focuses on Animal Stem Cell Therapy volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Animal Stem Cell Therapy market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan et

Animal Stem Cell Therapy Market Breakdown by Types:

Animal Stem Cell Therapy Market Breakdown by Application:

Critical highlights covered in the Global Animal Stem Cell Therapy market include:

The information available in the Animal Stem Cell Therapy Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Animal Stem Cell Therapy Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14828170

Reasons for Buy Animal Stem Cell Therapy Market Report:

In the end, Animal Stem Cell Therapy Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Nanosilver Paste Market Size 2020 define, describe, and technology, application, end user, region, commercial study Future Growth by 2026

Global Lug Caps Market Size 2020 Competitive benchmarking, Historical data, Company revenue shares, Regional opportunities, Latest trends & dynamics Future Growth by 2026

Global Coagulation Factors Market report is segmented into several key countries, with market size, growth rate, import and export in these countries from 2020 to 2026

Commercial Aircraft Tire Pressure Monitoring System Market Outlook 2024: Top Companies, consumption by Regional data, Investigation and growth Trends and Growth Factors Details for Business Development

Global Plastic Injection Molding Machine Auxiliary Equipment Market 2020 Analysis, Investigation Growth by Top Companies, consumption by Regional data, Trends by Types and Application, Forecast Analysis to 2026

Water Based Acrylates Copolymer Rheology Modifiers Market 2020 Analysis and In-Depth Research on Market Dynamics, consumption by Regional data, Trends, Investigation and Growth, Emerging Growth Factors and Forecasts To 2024

Global Metal-organic Frameworks Market Size 2020 drivers, opportunities, restraints, challenges, define and technology, application, end user, region, commercial study Future Growth by 2026

Global High-end Inertial Systems Market 2020 Top Companies report covers, Industry Outlook | In-depth Analysis Business Opportunities and Showing Impressive Growth by 2024

Global Traffic Signal Recognition Market 2020 is predicted to rise with a CAGR of by 2026 | According to Top Investors, Covering Sentimental Industry Analysis, Market Size & Growth

See the original post here:

Animal Stem Cell Therapy Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Market Size & Growth with Complete Business...

The study on Adipose Tissue-derived Stem Cell Therapy market provides thorough insights pertaining to major growth drivers, challenges, and opportunities that will influence the industry expansion in the forthcoming years.

According to the research document, the industry is expected to register XX% CAGR over the forecast period (2020-2025), subsequently accruing significant gains by the end of analysis timeframe.

The market is in a disarray due to the lockdowns imposed for limiting the spread of COVID-19 outbreak. In addition to the sudden slump of revenue, some businesses are expected to tackle a plethora of challenges post the pandemic.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/224665

Most of the businesses across various sectors have renewed their budgets to focus on profit gains in upcoming years. Our comprehensive analysis of the business sphere can help stakeholders in making sound decisions to compensate for market uncertainties and support them in building strong contingency plans.

Further, the report provides a granular assessment of the several industry segmentations to convey a deeper understanding of the areas with strong profit potential.

Key inclusions of the Adipose Tissue-derived Stem Cell Therapy market report:

Adipose Tissue-derived Stem Cell Therapy Market segments covered in the report:

Regional segmentation:

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Product types: Autologous Stem Cells and Allogeneic Stem Cells

Applications spectrum: Therapeutic Application and Research Application

Competitive outlook:

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the key factors driving the growth of the industry?

What are the emerging market trends and opportunities for this sector?

What is the future growth trend of this industry?

What is the size of the global and regional sector in terms of volume, size, and revenue?

Which is the most promising region in the global market?

What is the forecasted revenue and volume growth rates of the industry in the coming years?

Which region holds the highest share and what are the market shares of other key regions?

How will each segment and region grow over the years until 2025?

Table of Contents:

Report Overview: It includes major players of the global Adipose Tissue-derived Stem Cell Therapy market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Adipose Tissue-derived Stem Cell Therapy market by application, it gives a study on the consumption in the global Adipose Tissue-derived Stem Cell Therapy market by application

Company Profiles: Almost all leading players of the global Adipose Tissue-derived Stem Cell Therapy market are profiled in this section. The analysts have provided information about their recent developments in the global Adipose Tissue-derived Stem Cell Therapy market, products, revenue, production, business, and company.

Key Findings: This section gives a quick look at important findings of the research study.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/224665

Follow this link:

Adipose Tissue-derived Stem Cell Therapy Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal

Reportspedia has recently come up with a new market research report titled, Stem Cell Therapy Market. This statistical market study compromises an extensive understanding of the present-day and impending stages of the industry market based on factors such as major research skills, management schemes, drivers, restraints, opportunities, challenges, and visions include the subdivisions in the industries and regional distribution. Besides, this report emphasizes the latest events such as technological developments and product launches and their consequences on the Market. The research report delivers the global market revenue, parent market trends along with market attractiveness per market segment.

Get a Sample Copy of this [emailprotected]:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

Top Key Players:

Celgene CorporationOsiris Therapeutics, Inc.Pharmicell Co., LtdMEDIPOST Co., Ltd.Promethera BiosciencesFibrocell Science, Inc.Holostem Terapie Avanzate S.r.l.Cytori TherapeuticsNuvasive, Inc.RTI Surgical, Inc.Anterogen Co., Ltd.RTI Surgical, Inc

Regional Stem Cell Therapy Market (regional production, demand, and forecast by country):

The market specialists and researchers have done an all-encompassing breakdown of the global Stem Cell Therapy Market with the benefit of research methodologies such as PESTLE and Porters Five Forces analysis. They give precise and reliable market data and helpful recommendations with a means to support the players gain an insight into the overall current and upcoming market scenario. The report provides key statistics on the market status, size, share, growth factors of the Global Stem Cell Therapy industry.

Get Discount on This Precious Report @:

https://www.reportspedia.com/discount_inquiry/discount/57925

The main goals of the research report elegant the overall market overview on Stem Cell Therapy market dynamics, historic volume and value, newest and upcoming trends, Porters Five Forces Analysis, cost structure, government policies, and regulations, etc.

KEY MARKET SEGMENTS

On the basis of types, the Stem Cell Therapy Market is primarily split into:

Adult Stem CellsHuman EmbryonicInduced Pluripotent Stem CellsVery Small Embryonic Like Stem Cells

On the basis of applications, the Stem Cell Therapy Market covers:

Regenerative MedicineDrug Discovery and Development

This research report represents a 360-degree overview of the competitive landscape of the Meat Ingredients Market. Likewise, it offers enormous data relating to current trends, technological advancements, tools, and methodologies. The Stem Cell Therapy report thoroughly upholds the up-to-date state of dynamic segmentation of the Stem Cell Therapy Industry, highlighting major and revenue efficient market segments comprising the application, type, technology, and the like that together coin lucrative business returns in the Stem Cell Therapy market.

Inquiry Before [emailprotected]:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

Key Pointers of the Report:

Table of Contents

Global Stem Cell Therapy Market Research Report

Chapter 1 Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Stem Cell Therapy

Chapter 3 Global Stem Cell Therapy Market Competition by Key Players

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Stem Cell Therapy Industry Analysis by Application, Type

Chapter 6 Stem Cell Therapy Market Manufacturing Cost Analysis

Chapter 7 Marketing Strategy Analysis, Distributors/Traders

Chapter 9 Market Effect Factors Analysis

Chapter 9 Global Stem Cell Therapy Market Forecast

Get Full Table of content @:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

Read the original post:

Global Stem Cell Therapy Market 2020: Trends, and Opportunity Analysis, Top Manufacturers And Forecast to 2027 - PRnews Leader

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Therapy Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Therapy market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Stem Cell Therapy MarketIndustry / Sector Trends

Stem Cell Therapy Market size was valued at USD 7.8 billion in 2018 and is expected to witness 10.2% CAGR from 2021 to 2026.

U.S. Stem Cell Therapy Market Size, By Type, 2018 & 2025 (USD Million)

Rising prevalence of chronic diseases will positively impact the stem cell therapy market growth. Cardiovascular diseases, neurological disorders and other chronic conditions have resulted in high mortality over past few years. Conventional therapeutic methods and treatments are currently replaced due to lack of efficiency and efficacy. Recently developed stem cell therapies are capable of replacing defective cells to treat diseases that has reduced morbidity drastically. Therefore, people have now started relying on stem cell therapy that has long term positive effects.

Advancements in stem cell therapy in developed regions such as North America and Europe have boosted the industry growth. Since past few years, there have been several researches carried out for stem cell therapy. Currently developed stem cell therapies have shown positive outcomes in treatment of leukemia. Similarly, due to advancements in regenerative medicine, several other chronic conditions such as muscular dystrophy and cardiovascular diseases also have been cured. Aforementioned factors have surged the industry growth. However, high cost of allogenic stem cell therapy may hamper the industry growth to some extent.

Market Segmentation, Outlook & Regional Insights: Stem Cell Therapy Market

Stem Cell Therapy Market, By Type

Allogenic stem cell therapy segment held around 39% revenue share in 2018 and it is anticipated to grow substantially during the analysis timeframe. Allogenic stem cell is available as off the shelf therapy and it is easily scalable that helps in providing treatment without delay. Moreover, the procedure includes culturing donor-derived immunocompetent cells that are highly effective in treatment of several diseases. Stem cells obtained in allogenic therapy are free of contaminating tumor cells. This reduces risk for disease recurrence that will surge its demand thereby, stimulating segment growth.

Autologous stem cell therapy segment is estimated to witness 10.1% growth over the forthcoming years. People usually prefer autologous stem cell therapy as it has minimum risk of immunological rejection. However, on introduction of allogenic stem cell therapy, demand for autologous stem cell therapy has declined as it is difficult to scale up. However, there are concerns regarding risk of cross contamination during large scale manufacturing of autologous stem cell lines that will impede segmental growth to some extent.

Stem Cell Therapy Market, By Application

The neurology segment was valued at around USD 1.6 billion in 2018 and it is estimated that it will witness significant growth over the forthcoming years. Stem cells are used to replenish the disrupted neurological cells that help in quick patient recovery. Pluripotent stem cells provide a replacement for cells and tissues to treat Alzheimers, Parkinsons disease, cerebral palsy, amyotrophic lateral sclerosis, and other neurodegenerative diseases. Thus, the pivotal role of stem cells in treating the life-threatening neurological condition will escalate segment growth.

The cardiovascular segment will witness 10% growth over the analysis timeframe. Considerable segmental growth can be attributed to development in stem cell therapies that have enhanced recovery pace in patients suffering from cardiovascular diseases. Recently developed allogeneic stem cell therapies are efficient and easily available that have reduced the mortality rates in cardiovascular patients. Above mentioned factors will propel cardiovascular segment growth in near future.

Stem Cell Therapy Market, By End-users

The hospital segment held over 56% revenue share in 2018 and it is anticipated to grow significantly in near future. The rising preference for stem cell therapies offered by hospitals proves beneficial for business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On the introduction and approval of any novel stem therapy, hospitals implement it immediately. Associations with research and academic institutes further help hospitals to upgrade its stem cell treatment offerings that positively impact the segmental growth.

The clinics segment is expected to grow at around 10% during the forecast timeframe. Clinics specializing in providing stem cell therapies are well-equipped with advanced medical devices and superior quality reagents required for imparting stem cell therapies. However, as clinics offer specialized stem cell therapies, their treatment cost is much higher as compared to hospitals that may reduce its preference.

Stem Cell Therapy Market, By Region

North America stem cell therapy market held around 41.5% revenue share in 2018 and it is estimated to grow substantially in near future. Increasing the adoption of novel stem cell therapies will prove beneficial for regional market growth. Moreover, favorable government initiatives have a positive impact on regional market growth. For instance, the government of Canada has initiated Strategic Innovation Fund Program that invests in research activities carried out for stem cell therapies enabling development in stem cell therapy. Above mentioned factors are expected to drive the North America market growth.

Asia Pacific stem cell therapy market is anticipated to witness 10.8% growth in the near future owing to increasing awareness amongst people pertaining to the benefits of advanced stem cell therapies. Additionally, favorable initiatives undertaken by several organizations will promote industry players to come up with innovative solutions. For instance, according to Pharma Focus Asia, members of the Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research. Thus, growing initiatives by organizations ensuring the availability of new stem cell therapies will foster regional market growth.

Latin America Stem Cell Therapy Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Stem Cell Therapy Market

Key industry players in the stem cell therapy market include Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group, and Takeda Pharmaceuticals. Chief industry players implement several initiatives such as mergers and acquisitions to sustain market competition. Also, receiving approvals for stem cell therapy products from regulatory authorities fosters the companys growth. For instance, in March 2018, the European Commission approved Takedas Alofisel that is off-the-shelf stem cell therapy. Product approval will help the company to gain a competitive advantage and capture market share.

Stem Cell Therapy Industry Viewpoint

The stem cells industry can be traced back to the 1950s. In 1959 first animals were made by in-vitro fertilization by preserving the stem cells. Till 2000, research was being carried out on stem cells to study its therapeutic effect. In 2000, fund allocations were made to research on cells derived from aborted human fetuses. In the same year, scientists derived human embryonic stem cells from the inner cell mass of blastocytes. Later, in 2010, clinical trials for human embryonic stem cell-based therapy were initiated. As technology progressed, stem cell therapy for treating cancer was developed. However, due to ethical issues, the use of stem cells for curing diseases witnessed slow growth for a few years. But as the regulatory scenario changed, people started preferring stem cell therapies due to its better efficacy. Stem cell therapy is in the developing stage and has numerous growth opportunities in developing economies with a high prevalence of chronic diseases.

Key Industry Development

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

The proximity and structure of Takedas cell therapy teams allow them to quickly apply what they learn across a diverse portfolio of next-generation cell therapies including CAR NKs, armored CAR-Ts, and gamma delta T cells. Insights gained in manufacturing and clinical development can be quickly shared across global research, manufacturing, and quality teams, a critical ability in their effort to deliver potentially transformative treatments to patients as fast as possible.

Takeda and MD Anderson are developing a potential best-in-class allogeneic cell therapy product (TAK-007), a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with the potential for off-the-shelf use being studied in patients with relapsed or refractory non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Two additional Phase 1 studies of Takeda cell therapy programs were also recently initiated: 19(T2)28z1xx CAR T cells (TAK-940), a next-generation CAR-T signaling domain developed in partnership with Memorial Sloan Kettering Cancer Center (MSK) to treat relapsed/refractory B-cell cancers, and a cytokine and chemokine armored CAR-T (TAK-102) developed in partnership with Noile-Immune Biotech to treat GPC3-expressing previously treated solid tumors.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

Key Insights Covered: Exhaustive Stem Cell Therapy Market1. Market size (sales, revenue and growth rate) of Stem Cell Therapy industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Stem Cell Therapy industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Stem Cell Therapy industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Stem Cell Therapy industry.

Research Methodology: Stem Cell Therapy Market

Looking for more? Check out our repository for all available reports on Stem Cell Therapy in related sectors.

Quick Read Table of Contents of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

More here:

Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Eurowire

Global Adipose Tissue-derived Stem Cell Therapy Market Growth (Status and Outlook) 2020-2025 introduces the overview of the industry which clarifies the definition and specifications of Adipose Tissue-derived Stem Cell Therapy. The report explains a comparative assessment of the market. The report highlights a number of the main drivers and restraints factors influencing the expansion of the market. The report covers key trends and segmentation analysis, and all the regions. The report is crafted with figures, charts, tables, and facts to clarify, revealing the position of the specific sector at the regional and global levels. It comprises historical data, significance, statistical data, size & share, market analysis by product and market trends by key players, and market price & demand. The market is separated by product sort, application, and countries.

Competitive Rivalry:

As a part of the competitive landscape analysis, the report identifies the major competitors of the global Adipose Tissue-derived Stem Cell Therapy market along with their market share, company profile, current developments, core competencies and investments in each segment as well as product image and specification, sales and market share, material suppliers and major downstream consumers, producing base and price structure. The report provides a comprehensive analysis of the key business leaders and their present business environment and expected future development.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150959

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Global Adipose Tissue-derived Stem Cell Therapy market rivalry by leading manufacturers, together with production, cost, earnings (value) and market share for every producer; the best players as AlloCure, Tissue Genesis, Antria, Cellleris, Corestem, Celgene Corporation, Mesoblast, Cytori Therapeutics, Pluristem Therapeutics, Intrexon, Lonza, BioRestorative Therapies, Pluristem Therapeutics, iXCells Biotechnologies, Cyagen, Celltex Therapeutics Corporation,

On the basis of geography, the Adipose Tissue-derived Stem Cell Therapy market report covers data points for multiple geographies such as Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Scope of the Report:

The report provides an overall analysis of the global Adipose Tissue-derived Stem Cell Therapy market share, size, segmentation, revenue forecasts, and geographic regions covering the study of industry-leading players with respect to their company profile, product portfolio, capacity, price, cost, and revenue. The report analyzes industry drivers, obstacles, latest discoveries, and openings available for newcomers in the market. It provides an industry overview with growth analysis and futuristic cost, revenue, demand, and supply data. Under the regional analysis, this report focuses on product capacity, production, value, consumption, market share, and growth opportunity in regions.

For product type segment, this report listed the main product type of market: Autologous Stem Cells, Allogeneic Stem Cells,

For the application segment, this report focuses on the status and outlook for key applications. End users are also listed: Therapeutic Application, Research Application,

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150959/global-adipose-tissue-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025

The Outlook of Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketandresearch.biz

Other Related Reports Here:

Global Furan No-bake Resin Market 2020 Potential Growth, Competitive Landscape and Development of Industry by 2026

Global Strontium Chloride Hexahydrate Market 2020 Industry Analysis, Type and Application, Key Players, Regions, Forecast by 2026

Global Strontium Nitrate Market 2020 Industry Analysis by Manufacturers, End-User, Type, Application, Regions and Forecast to 2026

Global Strontium Sulfate Market 2020 Analytical Assessment, Key Drivers, Growth and Opportunities to 2026

Global Galantamine Hydrobromide Market 2020 Industry Growth, Top Players, Segmentation and Forecast to 2026

View post:

Global Adipose Tissue-derived Stem Cell Therapy Market 2020 Demand, Business Growing Strategies, Industry Segmentation and Forecast 2025 -...

The Stem Cell Therapy Market study analysis offers a complete evaluation of the Stem Cell Therapy Market which contains facts, thoughtful insights, historical data, and statistically supported and industry-validated market information. Stem Cell Therapy Market analyses also contain forecasts that are derived from an appropriate set of conventions and practices.

This research report is involved with the widespread usage of both primary & secondary data sources. The research report includes the analysis of several factors that are affecting the industry, along with the government policy, competitive landscape, and market environment, present trends in the market, technological development, upcoming technologies, and technical progress in related industries, and market risks, opportunities, market barriers, and challenges.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Stem Cell Therapy Market 2020 Industry Research Report is a professional and in-depth study on the current state of the Global Stem Cell Therapy industry. Moreover, research report categorizes the global Stem Cell Therapy market by top players/brands, region, type and end user. Stem Cell Therapy Market report also tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. It provides market size (value and volume), Stem Cell Therapy market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries.

Click to access the full report and Table of Content at https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Global Stem Cell Therapy Market: Competitive Analysis

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2015.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

The Stem Cell Therapy market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.

The key regions covered in the Stem Cell Therapy market report are:

1.North America (U.S., Canada)2.Europe (Germany, France, U.K., Italy, Russia)3.Asia-Pacific (China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam)4.Latin America (Mexico, Brazil, Argentina)5.Middle East & Africa (Turkey, Saudi Arabia, U.A.E.)

Some of the major objectives of this report:

1.To provide a detailed analysis of the market structure along with the forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.2.To provide insights about factors affecting market growth. To analyze the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, porter five force analyses, etc.3.To provide historical and forecast revenue of the Stem Cell Therapy Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and the Rest of the World.4.Country-level analysis of the market with respect to the current market size and future prospective.5.To provide country-level analysis of the market for segment by application, product type, and sub-segments.6.To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.7.Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Stem Cell Therapy Market.

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:

Stem Cell Therapy Market Trends, Opportunities, New Technologies and Developments, Competitor analysis and Market Sizing from 2020 to 2026 - PRnews...

An up-to-date intelligence study by Global Adipose Derived Stem Cell Therapy Market Growth (Status and Outlook) 2020-2025 provides the present scenario of the market and offers a comparative assessment of the market. The report provides historical data, significance, statistical data, size & share, market price & demand, business overview, market analysis by product and market trends by key players. It detects that the global Adipose Derived Stem Cell Therapy market by technological advancements and the presence of a large number of players, who are making the competitive landscape distributed. The report further highlights current growth factors, market threats, attentive opinions, and competitive analysis of major Adipose Derived Stem Cell Therapy market players, value chain analysis, and future roadmap.

Competitiveness:

The Adipose Derived Stem Cell Therapy market is fragmented and is characterized by the presence of key vendors and other prominent vendors. Key vendors are trying to maintain themselves in the global Adipose Derived Stem Cell Therapy market, whereas, regional vendors are focusing on product offerings to establish themselves in the market. Vendors are providing a different range of product lines intensifying the competitive scenario.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150958

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Market Potential:

The market vendors have been forecasted to obtain new opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Additionally, many of the market participants are anticipated to make a foray into the emerging economies that are yet to be explored so as to find new opportunities. The global Adipose Derived Stem Cell Therapy market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in the worldwide market.

Topmost list manufacturers/ key player/ economy by business leaders leading players of the market are: AlloCure, Tissue Genesis, Antria, Cellleris, Corestem, Celgene Corporation, Mesoblast, Cytori Therapeutics, Pluristem Therapeutics, Intrexon, Lonza, BioRestorative Therapies, Pluristem Therapeutics, iXCells Biotechnologies, Cyagen, Celltex Therapeutics Corporation,

Geographically, this report studies market share and growth opportunity in the following key regions: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

On the basis of product segment, this report covers: Autologous Stem Cells, Allogeneic Stem Cells,

On the basis of Application segment, this report covers: Therapeutic Application, Research Application,

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150958/global-adipose-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025

Important Take-Away:

Moreover, the report has covered the PEST analysis by region and key economies across the globe, PORTERs analysis, and detailed SWOT analysis of key players to analyze their strategies. It guides companies to make effective business strategy decisions by knowing the global Adipose Derived Stem Cell Therapy market conditions and sentiment within the market. The report serves to adjust investment allocation by outlining key focus areas of the industry.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketandresearch.biz

Other Related Reports Here:

Global Myristamine Oxide Market 2020 Industry Growth Analysis by Key Players, Segments, Competitive Landscape and Forecast to 2026

Global Rivastigmine Tartrate Market 2020 Emerging Trend, Top Companies, Industry Demand, Business Review and Regional Analysis by 2026

Global 3-Methoxy-3-Methyl-1-Butanol Market 2020 Industry Status and Outlook, Competitive Landscape and Growth by 2026

Global Sodium Tetra Sulphide Market 2020 Industry Analysis, Size, Share, Growth, Trend and Forecast to 2026

Global 3-Chloropivaloyl Chloride Market 2020 by Key Players, Regions, Type and Application, Forecast to 2026

Read more:

Global Adipose Derived Stem Cell Therapy Market 2020 Demand, Business Growing Strategies, Industry Segmentation and Forecast 2025 - TechnoWeekly

TORONTO, Oct. 19, 2020 /PRNewswire/ --Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corporate Development, effective immediately.

"Adding these experienced leaders to our team underpins our strategy of advancing our pipeline and supporting our partnering initiatives," said David Main, President and Chief Executive Officer of Notch. "Their combined expertise in financial and corporate strategy will augment our deep technical team as we advance our proprietary platform that enables the development of highly consistent T cell therapies manufactured at industrial scale and lower cost. We look forward to their contributions as members of our executive team."

Kamran Alam, Executive Vice President, Finance and Chief Financial OfficerKamran Alam brings to Notch more than 20 years of global corporate finance and business development leadership experience. He joins Notch from Neoleukin Therapeutics, where he served as Interim Chief Financial Officer following Neoleukin's merger in 2018 with Aquinox Pharmaceuticals. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange in 2014. Prior to his tenure with Aquinox, Mr. Alam held senior roles in business development for a number of biotechnology and pharmaceutical companies. Mr. Alam is a Chartered Professional Accountant. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria.

Gregory Block, Ph.D., Senior Vice President, Corporate DevelopmentGregory Block is a seasoned biotechnology executive with more than 10 years of experience in the development and commercialization of novel therapeutic modalities. Prior to his position with Notch, he served as Director of Business Development for Astellas Pharmaceuticals, where he led business development and strategic initiatives for regenerative medicine and cell therapy immune oncology. Dr. Block joined Astellas via the company's 2018 acquisition of Universal Cells Inc., where he was instrumental in company-building and business development. Dr. Block holds a Ph.D. in Molecular Biology from Tulane University and completed a fellowship at the University of Washington.

About Notch Therapeutics (www.notchtx.com)Notch Therapeutics is a cell therapy company that has unlocked the ability to produce T cells and other cells from any source of stem cells. At the core of the Notch technology is the Engineered Thymic Niche (ETN) platform, which enables precision control of cell fate during the differentiation and expansion of stem cells. The ETN is the first technology that can reliably generate T-cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents at industrial scale. By leveraging the ETN platform, Notch is positioned to design and deliver the next generation of T cell therapeutics that are specifically engineered to address the underlying biology of complex disease systems. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

See the original post here:

Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire

Global Stem Cell Therapy Market was valued at USD 117.66 million in 2019 and is projected to reach USD 255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2020 to 2027.

The Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113

Competitive Analysis:

The competitive analysis covers key players and the innovations and business strategies undertaken by them. The report captures the best long term growth opportunities for the sector and includes the latest process and product developments. The report includes basic information of the companies along with their market position, historical background, and market capitalization and revenue. The report covers revenue figures, market growth rate, and gross profit margin of each player based on regional classification and overall market position. The report provides a separate analysis of the recent business strategies such as mergers, acquisitions, product launches, joint ventures, partnerships, and collaborations.

Key features of the Report:

Leading players of Stem Cell Therapy including:

You can Buy This Report from Here @ https://www.verifiedmarketresearch.com/select-licence/?rid=24113

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request a discount on the report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

To understand the global Stem Cell Therapy market dynamics, the market is analyzed across major global regions and countries. Market Research Intellect provides customized specific regional and country-wise analysis of the key geographical regions as follows:

North America: USA, Canada, Mexico

Latin America: Argentina, Chile, Brazil, Peru, and Rest of Latin America

Europe:K., Germany, Spain, Italy, and Rest of EU

Asia-Pacific: India, China, Japan, South Korea, Australia, and Rest of APAC

Middle East & Africa: Saudi Arabia, South Africa, U.A.E., and Rest of MEA

The report considers:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Benefits of Stem Cell Therapy Market Report:

Report Overview with TOC:

Browse the complete report Along with TOC @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/

Thank you for reading our report. Customization of the report is also available on the basis of region and countries. Kindly get in touch with us for more information regarding the report and its customization. Our team will ensure the report is best suited according to your needs.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: sales@verifiedmarketresearch.com

Link:

Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Stock Market Vista

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.

The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.

The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.

The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.

Use-type Insights

The clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.

In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.

On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Therapy Type Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.

However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.

Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.

Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.

Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

The proximity and structure of Takedas cell therapy teams allow them to quickly apply what they learn across a diverse portfolio of next-generation cell therapies including CAR NKs, armored CAR-Ts, and gamma delta T cells. Insights gained in manufacturing and clinical development can be quickly shared across global research, manufacturing, and quality teams, a critical ability in their effort to deliver potentially transformative treatments to patients as fast as possible.

Takeda and MD Anderson are developing a potential best-in-class allogeneic cell therapy product (TAK-007), a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with the potential for off-the-shelf use being studied in patients with relapsed or refractory non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Two additional Phase 1 studies of Takeda cell therapy programs were also recently initiated: 19(T2)28z1xx CAR T cells (TAK-940), a next-generation CAR-T signaling domain developed in partnership with Memorial Sloan Kettering Cancer Center (MSK) to treat relapsed/refractory B-cell cancers, and a cytokine and chemokine armored CAR-T (TAK-102) developed in partnership with Noile-Immune Biotech to treat GPC3-expressing previously treated solid tumors.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing and control (CMC), data management, analytical and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

By Cell Type

Non-stem Cell Therapies

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Looking for more? Check out our repository for all available reports on Cell Therapy in related sectors.

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Here is the original post:

Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Eurowire

Stem Cell Therapy Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

A rise in disposable income among people across the world over the years has amplified developments in the healthcare industry and lead to the development of stem cell therapies, due to the demands of people for advanced and latest medical technologies. Investments infused by the governments especially in developing countries to improve the medical sector has supplemented advancements in the industry over time.

Request for a sample copy of this report @https://www.decresearch.com/request-sample/detail/3331

Research carried out to develop innovative therapies and personalized medicines to meet targeted medical needs has amplified the adoption stem cell therapeutics. The scientists, for instance, are extensively working on ways to regenerate heart cells from the placenta that may be used in patients after myocardial infarction. This will help to relieve the patients who are diagnosed with cardiovascular diseases in order to control the mortality rates.

The researchers are also discovering different aspects of stem cell therapy for its use in neurological disorders. Explained below are some of the main factors impacting stem cell therapy market size in the coming years, which is anticipated to reach USD 15 billion in yearly revenues by 2025.

Growing prevalence of chronic diseases owing to genetic disorders and unhealthy lifestyle adoption among masses will positively impact stem cell therapy market outlook. Stem cell therapy offers various benefits over conventional therapeutic methods, which makes it preferable for curing degenerative cell disorders. For instance, researchers are extensively seeking to regenerate healthy heart cells from placenta to treat patients after myocardial infarction. Advancing researches in stem cell therapy offer better prospects for curing cardiovascular diseases and minimizing mortality rates.

Geriatric population is susceptible to degenerative diseases such as Alzheimer's and Parkinson's disorders. Recent stem cell therapies aid production of healthy cells by replacing the defective cells via minimally invasive techniques. Geriatric population will come to heavily rely on stem cell therapies and hence add impetus to stem cell therapy market trend for expansion.

Stem cell therapy is gaining popularity owing to application in treatment of bone-joint injuries, which may include fractured bones and spinal defects, femoral head, osteogenesis imperfecta and ligament tendon. To cure orthopedic diseases such as osteoporosis and arthritis, mesenchymal stem cell therapy is gaining traction due to its ability to differentiate into cartilage and bone.

With rise in accidents and trauma cases that are being registered across the globe, stem cell therapy industry is estimated to garner considerable proceeds from orthopedic segment. Over the forecast timeline, orthopedic segment is projected to witness growth of more than 9%.

Rising government initiatives for promoting stem cell therapy in developing countries will propel stem cell therapy industry growth in the APAC region. Governments across developing countries are encouraging researchers and scientists to carry out studies to advance stem cell therapies in order to develop innovative solutions for treating chronic diseases. Moreover, many countries in the region are being backed by government funds to establish stem cell centers. For instance, Biopolis, a biomedical research center for stem cell research has been established by Singapore JTC Corporation. Such government initiatives in Asian countries are estimated to expand stem cell therapy market share. In 2018, APAC stem cell therapy market held around 20% revenue garnered by the global stem cell therapy market.

Browse full table of contents (TOC) of this report @https://www.decresearch.com/toc/detail/stem-cell-therapy-market

Partial Chapter of the Table of Content

Chapter 4. Stem Cell Therapy Market, By Type

4.1. Key segment trends

4.2. Allogenic stem cell therapy

4.2.1. Market size, by region, 2014-2025 (USD Million)

4.3. Autologous stem cell therapy

4.3.1. Market size, by region, 2014-2025 (USD Million)

Chapter 5. Stem Cell Therapy Market, By Application

5.1. Key segment trends

5.2. Oncology

5.2.1. Market size, by region, 2014-2025 (USD Million)

5.3. Orthopedic

5.3.1. Market size, by region, 2014-2025 (USD Million)

5.4. Cardiovascular

5.4.1. Market size, by region, 2014-2025 (USD Million)

5.5. Neurology

5.5.1. Market size, by region, 2014-2025 (USD Million)

5.6. Others

5.6.1. Market size, by region, 2014-2025 (USD Million)

See the original post here:

Stem Cell Therapy Market 2020 growth factors, latest trend and regional analysis of leading players by 2025 - News by Decresearch

Transparency Market Research (TMR) has published a new report titled, Autologous cell therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global autologous cell therapy market was valued at US$ 7.5 Bn in 2018 and is projected to expand at a CAGR of 18.1% from 2019 to 2027.

Overview

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=715

Rise in Prevalence of Neurological Disorders & Cancer and Others to Drive Market

Request for Analysis of COVID19 Impact on Autologous Cell Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=715

Bone Marrow Segment to Dominate Market

Neurology Segment to be Highly Lucrative Segment

Buy Autologous Cell Therapy Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=715&ltype=S

Hospitals Segment to be Highly Lucrative Segment

North America to Dominate Global Market

Competitive Landscape

The global autologous cell therapy market is fragmented in terms of number of players. Key players in the global market include Pharmicell Co., Inc., Castle Creek Biosciences, Inc., Vericel Corporation, Lineage Cell Therapeutics, Inc., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Opexa Therapeutics, Inc., Regeneus Ltd., Takeda Pharmaceutical Company Limited., Sangamo Therapeutics, U.S. Stem Cell, Inc. and other prominent players.

More Trending Reports by Transparency Market Research

Genome Engineering Market https://www.prnewswire.com/news-releases/genome-engineering-market-to-clock-cagr-of-10-9-from-2019-to-2027-crispr-gene-edition-tools-present-sizable-revenue-streams-tmr-301073517

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

More:

Autologous Cell Therapy Market is Anticipated to Expand at a CAGR of 18.1% from 2019 to 2027 - Eurowire

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Cell Therapy Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Cell Therapy market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Cell Therapy market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Cell Therapy market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cell Therapy market.

Key questions answered in the report:

TOC

1 Market Overview of Cell Therapy1.1 Cell Therapy Market Overview1.1.1 Cell Therapy Product Scope1.1.2 Market Status and Outlook1.2 Global Cell Therapy Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Cell Therapy Market Size by Region (2015-2026)1.4 Global Cell Therapy Historic Market Size by Region (2015-2020)1.5 Global Cell Therapy Market Size Forecast by Region (2021-2026)1.6 Key Regions, Cell Therapy Market Size YoY Growth (2015-2026)1.6.1 North America Cell Therapy Market Size YoY Growth (2015-2026)1.6.2 Europe Cell Therapy Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Cell Therapy Market Size YoY Growth (2015-2026)1.6.4 Latin America Cell Therapy Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Cell Therapy Market Size YoY Growth (2015-2026) 2 Cell Therapy Market Overview by Type2.1 Global Cell Therapy Market Size by Type: 2015 VS 2020 VS 20262.2 Global Cell Therapy Historic Market Size by Type (2015-2020)2.3 Global Cell Therapy Forecasted Market Size by Type (2021-2026)2.4 Stem Cell2.5 Non-Stem Cell 3 Cell Therapy Market Overview by Application3.1 Global Cell Therapy Market Size by Application: 2015 VS 2020 VS 20263.2 Global Cell Therapy Historic Market Size by Application (2015-2020)3.3 Global Cell Therapy Forecasted Market Size by Application (2021-2026)3.4 Hospital3.5 Clinic 4 Global Cell Therapy Competition Analysis by Players4.1 Global Cell Therapy Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Therapy as of 2019)4.3 Date of Key Manufacturers Enter into Cell Therapy Market4.4 Global Top Players Cell Therapy Headquarters and Area Served4.5 Key Players Cell Therapy Product Solution and Service4.6 Competitive Status4.6.1 Cell Therapy Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Gilead Sciences5.1.1 Gilead Sciences Profile5.1.2 Gilead Sciences Main Business5.1.3 Gilead Sciences Products, Services and Solutions5.1.4 Gilead Sciences Revenue (US$ Million) & (2015-2020)5.1.5 Gilead Sciences Recent Developments5.2 Novartis5.2.1 Novartis Profile5.2.2 Novartis Main Business and Companys Total Revenue5.2.3 Novartis Products, Services and Solutions5.2.4 Novartis Revenue (US$ Million) (2015-2020)5.2.5 Novartis Recent Development and Reaction to Covid-195.3 Osiris5.5.1 Osiris Profile5.3.2 Osiris Main Business5.3.3 Osiris Products, Services and Solutions5.3.4 Osiris Revenue (US$ Million) & (2015-2020)5.3.5 Vericel Corporation Recent Developments5.4 Vericel Corporation5.4.1 Vericel Corporation Profile5.4.2 Vericel Corporation Main Business5.4.3 Vericel Corporation Products, Services and Solutions5.4.4 Vericel Corporation Revenue (US$ Million) & (2015-2020)5.4.5 Vericel Corporation Recent Developments5.5 Vcanbio5.5.1 Vcanbio Profile5.5.2 Vcanbio Main Business5.5.3 Vcanbio Products, Services and Solutions5.5.4 Vcanbio Revenue (US$ Million) & (2015-2020)5.5.5 Vcanbio Recent Developments5.6 Fujifilm Cellular Dynamics5.6.1 Fujifilm Cellular Dynamics Profile5.6.2 Fujifilm Cellular Dynamics Main Business5.6.3 Fujifilm Cellular Dynamics Products, Services and Solutions5.6.4 Fujifilm Cellular Dynamics Revenue (US$ Million) & (2015-2020)5.6.5 Fujifilm Cellular Dynamics Recent Developments5.7 JCR Pharmaceuticals5.7.1 JCR Pharmaceuticals Profile5.7.2 JCR Pharmaceuticals Main Business and Companys Total Revenue5.7.3 JCR Pharmaceuticals Products, Services and Solutions5.7.4 JCR Pharmaceuticals Revenue (US$ Million) (2015-2020)5.7.5 JCR Pharmaceuticals Recent Development and Reaction to Covid-195.8 Beike Biotechnology5.8.1 Beike Biotechnology Profile5.8.2 Beike Biotechnology Main Business5.8.3 Beike Biotechnology Products, Services and Solutions5.8.4 Beike Biotechnology Revenue (US$ Million) & (2015-2020)5.8.5 Beike Biotechnology Recent Developments5.9 Golden Meditech5.9.1 Golden Meditech Profile5.9.2 Golden Meditech Main Business5.9.3 Golden Meditech Products, Services and Solutions5.9.4 Golden Meditech Revenue (US$ Million) & (2015-2020)5.9.5 Golden Meditech Recent Developments5.10 Guanhao Biotech5.10.1 Guanhao Biotech Profile5.10.2 Guanhao Biotech Main Business5.10.3 Guanhao Biotech Products, Services and Solutions5.10.4 Guanhao Biotech Revenue (US$ Million) & (2015-2020)5.10.5 Guanhao Biotech Recent Developments 6 North America6.1 North America Cell Therapy Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Cell Therapy Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Cell Therapy Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Cell Therapy Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Cell Therapy Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Cell Therapy Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:

Cell Therapy Market Trend,COVID-19 Impact,Current Industry Figures With Demand By Countries And Future Growth - PRnews Leader

Oct. 13, 2020 12:01 UTC

Organizations to work together to integrate Be The Match BioTherapies existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)-- Gamida Cell Ltd.. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cells advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell (bone marrow) transplant. The broadened agreement represents an important step in both organizations patient access efforts and in Gamida Cells preparation for potential approval by the U.S. Food and Drug Administration (FDA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005030/en/

The original partnership agreement between the organizations focused on the omidubicel development program and leveraged a wide range of Be The Match BioTherapies capabilities and services. This included providing cellular source material from the Be The Match Registry, which offers the most ethnically diverse listing of potential donors and umbilical cord blood units in the world, with 22 million potential donors and more than 300,000 umbilical cord blood units, as well as cell therapy supply chain and logistics management services. In building upon the existing collaboration, Gamida Cell will work through Be The Match BioTherapies for the ordering and supply of cord blood units, which serve as the starting material for omidubicel. The expanded agreement is designed to provide a smooth process throughout the omidubicel therapy supply chain.

Gamida Cells work to bring a new stem cell graft source to patients aligns with our core mission to help organizations deliver cellular therapies that can save more lives and improve the quality of life for patients, said Amy Ronneberg, chief executive officer of the National Marrow Donor Program/Be The Match and Be The Match BioTherapies. Were delighted to expand upon our collaboration to more fully leverage our infrastructure and technology to support the advancement of Gamida Cells efforts to seamlessly bring omidubicel to patients in clinical and commercial settings. Gamida Cells efforts to make stem cell transplant more accessible to patients could be particularly impactful for patients who do not have a matched donor of suitable age.

Be The Match BioTherapies is a respected leader in cell therapy and has an extensive history of assuring broad transplant access through the delivery of source material, globally, for patients in need of a transplant, stated Michele Korfin, chief operating and commercial officer of Gamida Cell. Deepening our collaboration represents an important step for Gamida Cell as the company increases its focus on potentially bringing omidubicel to patients in the commercial setting after reporting that omidubicel met its primary endpoint and all three secondary endpoints in our randomized, multi-center Phase 3 study. We look forward to our continued collaboration with Be The Match BioTherapies to ensure that we have an efficient and reliable cell therapy supply chain that can provide a positive experience for transplant teams and their patients.

In May, Gamida Cell reported that its Phase 3 study of omidubicel met its primary endpoint, demonstrating a highly statistically significant reduction in time to neutrophil engraftment, a key milestone in recovery from a stem cell transplant. Additionally, in October, Gamida Cell reported that all three secondary endpoints for the study related to platelet engraftment, infections and hospitalizations demonstrated statistical significance. Gamida Cell expects to begin submitting the biologics license application for omidubicel to the FDA on a rolling basis in the fourth quarter of 2020.

Despite the curative potential of bone marrow transplants, it is estimated that more than 40 percent of eligible patients in the U.S. do not receive one for various reasons, including difficulty in finding a matched donor. Omidubicel is designed to potentially serve as a universal alternative to existing donor sources for bone marrow transplant.

About Omidubicel Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). In clinical studies (NCT01816230 and NCT02730299), omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated. Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit http://www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit http://www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

About Be The Match BioTherapies Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program (NMDP)/Be The Match, and a research partnership with the CIBMTR (Center for International Blood and Marrow Transplant Research), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry, the worlds largest and most diverse registry of more than 22 million potential blood stem cell donors and more than 300,000 umbilical cord blood units. Through established relationships with apheresis, marrow collection and transplant centers worldwide, the organization develops, onboards, trains and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses a proven integrated model of both cell therapy supply chain and logistics managers, complimented by regulatory compliance experts to successfully transport and deliver life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visit http://www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.

Gamida Cell Forward Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the effect on any cell therapy supply chain or Gamida Cells anticipated timing regulatory filing submissions for omidubicel, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the ongoing global COVID-19 pandemic and manufacturing, clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cells Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on February 26, 2020, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005030/en/

Follow this link:

Gamida Cell and Be The Match BioTherapies Expand Strategic Collaboration - BioSpace

Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (2nd Edition), 2018-2030 report to its list of offerings.

Natasha Thakur, the principal analyst, stated, The growing number of cell therapy candidates continues to create an increasing demand for facilities that offer manufacturing services for these complex pharmacological interventions. Presently, over 145 companies / organizations are actively offering manufacturing services for such products. The installed global manufacturing capacity is estimated to be over 1 billion sq ft, with the maximum capacity available in North America

The report presents opinions on several key aspects of the market. Among other elements, it includes:

The report features inputs from a number of eminent industry stakeholders. Thakur remarked, Most of the experts we spoke to confirmed that the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with setting-up such facilities. The report features detailed transcripts of discussions held with the following experts:

The research also includes detailed profiles of the following players:

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing-market-2nd-edition-2018-2030/209.hl or email [emailprotected]

Contact:

Gaurav Chaudhary

+1-604-595-4954

Go here to read the rest:

Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - The Think Curiouser

A company born at the University of Louisville has raised an additional $115 million to further develop a therapy that could improve the lives of kidney transplant recipients.

The company, Talaris Therapeutics Inc., plans to use the series B funding to support a Phase 3 clinical trial the last step before applying for FDA approval. This follows a $100 million series A funding round announced last year to hire staff and initiate the trial.

Talaris recently began dosing patients in that trial of the unique cell therapy, called FCR001, which allows living-donor kidney transplant recipients to stay off immunosuppression drugs they would otherwise need for the rest of their lives.

Immunosuppressants help prevent rejection of the transplanted organ, but can cause side effects, including high blood pressure, diabetes, high cholesterol, neurological effects, increased risk of infection and decline in kidney function over time.

This technology could help transplant patients live fuller, healthier lives,said UofL Executive Vice President for Research and Innovation, Kevin Gardner.This UofL research, in the hands of strong industry partners and backed by investors, is a big step in advancing our health.

FCR001 consists of stem cells taken from the organ donor and processed at the Talaris facility, then infused into the organ transplant recipient. The goal is to create a durable dual immune system (part donor-derived and part recipient) in the transplant recipient. These two immune systems coexist, recognizing both the recipients own body as well as the donated organ as self.

The new funding also will advance aplanned Phase 2 trial of FCR001 in diffuse systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.

Talaris, formerly known as Regenerex LLC, was founded by UofL researcher and innovator Suzanne Ildstad to commercialize the pioneering work of her team at the university. She now serves as Talaris chief scientific officer.

This financing moves us one step closer to helping organ transplant recipients no longer be dependent on immunosuppressive drugs, resulting in a greatly improved quality of life, Ildstad said of the earlier Phase 3 trial financing. The support and research infrastructure at UofL have been invaluable in our journey to this important juncture.

In an earlier Phase 2 trial, FCR001 allowed 70% of living donor kidney transplant patients durably to be weaned off all of their immunosuppression treatments.

The Phase 3 trial is expected to enroll 120 adult living donor kidney transplant recipients at multiple sites across the U.S. To date, the trial has been initiated at five clinical sites around the country.

Excerpt from:

UofL-born company secures an additional $115 million to advance cell therapy - uoflnews.com

Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite

"Novellus's iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of their high potency as demonstrated in our pre-clinical studies, as well as our ability to cost-effectively provide high doses and repeat doses." said Myron Holubiak, CEO of Citius.

"We are excited to be developing iMSCs because of their promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Matt Angel, Chief Science Officer of Novellus. He continued, "Our iMSCs have multimodal immunomodulatory mechanisms of action that make them promising for treatment of acute respiratory diseases."

About Novellus Therapeutics LimitedNovellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA, high-specificity gene editing, mutation-free & footprint-free cell reprogramming and serum-insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellustx.com.

About NoveCite, Inc.NoveCite, Inc. is a newly formed subsidiary of Citius Pharmaceuticals, a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

Contact: [emailprotected]

SOURCE Novellus Therapeutics

More:

Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome...

The Global and United States Cancer Stem Cell Therapy Market report offers a complete research study that includes accurate estimations of market growth rate and size for the forecast period 2020-2026. It offers a broad analysis of market competition, regional expansion, and market segmentation by type, application, and geography supported by exact market figures. The all-inclusive market research report also offers Porters Five Forces Analysis and profiles some of the leading players of the global Global and United States Cancer Stem Cell Therapy Market. It sheds light on changing market dynamics and discusses about different growth drivers, market challenges and restraints, and trends and opportunities in detail. Interested parties are provided with market recommendations and business advice to ensure success in the global Global and United States Cancer Stem Cell Therapy Market.

Top Key Key Players Covered In This Report: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.supplydemandmarketresearch.com/home/contact/1507021?ref=Sample-and-Brochure&toccode=SDMRME1507021

Leading players of the Global and United States Cancer Stem Cell Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Global and United States Cancer Stem Cell Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Global and United States Cancer Stem Cell Therapy Market. It also provides useful recommendations for new as well as established players of the Global and United States Cancer Stem Cell Therapy Market.

Final Global and United States Cancer Stem Cell Therapy Report will add the analysis of the impact of COVID-19 on this Market.

Global and United States Cancer Stem Cell Therapy Market Type (Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Other) Application (Hospital, Clinic, Medical Research Institution, Other) Global Trends and Forecasts to 2025

Industry Insights

The Global and United States Cancer Stem Cell Therapy Market is expected to grow at a CAGR of XX % during the forecast period 2018-2025.

The Global and United States Cancer Stem Cell Therapy Market is segmented on the basis of Type and Application. The Global and United States Cancer Stem Cell Therapy Market is segmented based on the basis of typeAutologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Other. By Application, it is classified as Hospital, Clinic, Medical Research Institution, Other. The regional outlook on the Global and United States Cancer Stem Cell Therapy Market covers regions, such as North America, Europe, Asia-Pacific, and Rest of the World. Global and United States Cancer Stem Cell Therapy Market for each region is further bifurcated for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Report Scope:

The Global and United States Cancer Stem Cell Therapy Market report scope covers the in-depth business analysis considering major market dynamics, forecast parameters, and price trends for the industry growth. The report forecasts market sizing at global, regional and country levels, providing comprehensive outlook of industry trends in each market segments and sub-segments from 2017 to 2024. The market segmentations include

Globaland United States Cancer Stem Cell Therapy Market, By Type

Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Other

In the same way, the study has divided by applications

Global and United States Cancer Stem Cell Therapy Market, By Application

Hospital, Clinic, Medical Research Institution, Other

Global and United States Cancer Stem Cell Therapy Market, By Region

The report scope also includes competitive landscape covering the competitive analysis, strategy analysis and company profiles of the major market players. The companies profiled in the report includeAVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems

Report Highlights

How this report will add value to your organisation

This report provides the in-depth analysis of the complete value chain from the raw material suppliers to the end users. We have critically analysed following parameters and their impact in the industry:

1. Improvement in top line and bottom line growth

Analysis trend & forecasts by end use markets will help you to understand how the growth in consumption is expected in next 5 years and what will be the key factors that will support the growth. This will help to make a clear plan for the top line growth. Price analytics will also play a crucial role in making a plan for top line growth.

Raw material and other input factors analysis will help to plan effectively for the bottom line.

2. Competitive intelligence

In a competitive marketplace, up-to-date information can make the difference between keeping pace, getting ahead, or being left behind. A smart intelligence operation can serve as an early-warning system for disruptive changes in the competitive landscape, whether that change is a rivals new product or pricing strategy or the entrance of an unexpected player into your market.

We also provide you with information that allows you to anticipate what your competitors are planning next. For example, you might gain information on a new product they are getting ready to launch or new services they will add to the business. Hiring us to handle this information collection saves you time and energy, allowing you to focus on your own business while still gaining the necessary knowledge to keep track of competitors.

3. Identification of prospective customers and their satisfaction level with the current supplier:

We have provided the long list of customers and analysed them critically, based on various parameters such as consumption, market type, sustainable business etc. this will help your organisation to develop relations with the consumers. Also, we have identified the factors in which the others customer will switch to you.

Report Customizations

The customization research services cover the additional custom report features such as additional regional and country level analysis as per the client requirements.

Grab Best Discount on Global and United States Cancer Stem Cell Therapy Market Research Report [Single User | Multi User | Corporate Users] @ https://www.supplydemandmarketresearch.com/home/contact/1507021?ref=Discount&toccode=SDMRME1507021

About SDMR: We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us: Mr. Charles Lee302-20 Misssisauga, Valley, Missisauga,L5A 3S1, Toronto, Canada Phone Number: +1-276-477-5910Email- [emailprotected]

See the article here:

Global and United States Cancer Stem Cell Therapy Market Leading Players Expected to Witness the Highest Growth 2025 | AVIVA BioSciences, AdnaGen,...

In recent years, stem cell therapy has been hailed as a miracle cure for many conditions, from wrinkles to spinal repair. In animal studies, stem cell treatments have shown promise for various diseases, including heart disease, Parkinsons disease and muscular dystrophy.

Stem cell therapy could also potentially treat osteoarthritis (OA) of the knee. In OA, the cartilage covering the ends of the bones starts to deteriorate and wear away. As the bones lose this protective covering, they start to rub against one another. This leads to pain, swelling, and stiffness and, ultimately, loss of function and mobility.

Millions of people in the United States live with OA of the knee. Many manage their symptoms through exercise, weight loss, medical treatments, and lifestyle modification.

If symptoms become severe, total knee replacement is an option. Over 600,000 people a year undergo this operation in the United States alone. Yet stem cell therapy can be an alternative to surgery.

The human body is constantly manufacturing stem cells in the bone marrow. Based on certain conditions and signals in the body, stem cells are directed to where they are needed.

A stem cell is an immature, basic cell that has not yet developed to become, say, a skin cell or a muscle cell or a nerve cell. There are different types of stem cells that the body can use for different purposes.

There is evidence that stem cell treatments work by triggering damaged tissues in the body to repair themselves. This is often referred to as regenerative therapy.

However, research into stem cell treatment for OA of the knee is somewhat limited, and the results of studies are mixed.

The American College of Rheumatology and the Arthritis Foundation (ACR/AF) do not currently recommend stem cell treatment for OA of the knee, for the following reasons:

Currently, the Food & Drug Administration (FDA) considers stem cell treatment investigational. Until additional studies can demonstrate a clear benefit from stem cell injections, people who opt for this treatment must pay for them on their own and must understand that the treatment may not work.

That said, as researchers learn more about this type of treatment, it could one day become a viable option for the treatment of OA.

The cartilage covering the ends of the bones enables the bones to glide smoothly against one another with only slight friction. OA causes damage to the cartilage and leads to increased friction resulting in pain, inflammation, and ultimately, a loss of mobility and function.

In theory, stem cell therapy uses the bodys own healing mechanisms to help repair and slow the deterioration of body tissues, such as cartilage.

Stem cell therapy for knees aims to:

In simple terms, treatment involves:

Several studies have concluded that stem cell therapy improves arthritis symptoms of the knee. While overall results are promising, more research is needed to discover:

Stem cell treatment for knees is noninvasive, and studies suggest that side effects are minimal.

After the procedure, some people may experience temporary increased pain and swelling. However, the overwhelming majority of people who get stem cell injections have no adverse side effects.

The procedure uses stem cells that come from your own body. In theory, this dramatically reduces the risk of any serious side effects. However, there are various ways of harvesting and processing the stem cells, which likely affects the various success rates of the published studies.

Before receiving any treatment, its best to:

Despite conflicting evidence about whether stem cell injections work, many clinics offer them as an option for the treatment of arthritic knee pain.

Since stem cell treatment for arthritic knee pain is still considered investigational by the FDA, the treatment is not yet standardized and there is no limit to what doctors and clinics can charge.

The cost can be several thousands of dollars per knee and most insurance companies do not cover the treatment.

If OA is causing knee pain or affecting your mobility, the ACR/AF recommend the following options:

If these dont work or become ineffective, a total knee replacement surgery may be an option. Knee replacement surgery is a very common operation that can greatly improve mobility, decrease pain, and significantly improve quality of life.

Research into stem cell therapy for treatment of osteoarthritic knee pain is ongoing. Some research has shown promising results and it may one day become an accepted treatment option. For now, it remains costly and experts remain cautiously optimistic.

View post:

Can Stem Cell Therapy Repair Damaged Knees?